Drug Ther Bull. 2011 Apr;49(4):42-5; quiz i-ii. doi: 10.1136/dtb.2011.02.0022.
Colorectal cancer is the third commonest malignancy worldwide and the second commonest cause of cancer-related deaths.1,2 Around 15-25% of patients with colorectal cancer have metastases at presentation, and a further 20-25% develop them subsequently.3 Management for metastatic disease is mainly palliative and traditionally 5-year survival has been rare.3-5 In colorectal cancer, metastases mostly occur in the liver and in 30-50% of patients with liver involvement, this is the only site of spread. For those with liver-only metastases, resection of these lesions provides a chance of longer-term survival or even cure (e.g. 5-year survival 25-71%).4,6-13 Here we focus on recent advances in chemotherapy for patients with initially unresectable liver metastases, aimed at rendering such lesions operable, with potential improvements in survival.4,13,14.
结直肠癌是全球第三大常见恶性肿瘤，也是癌症相关死亡的第二大常见原因。1,2 约15%-25%的结直肠癌患者在初诊时已有转移，另有20%-25%的患者随后会发生转移。3 转移性疾病的治疗主要是姑息性的，传统上5年生存率很低。3-5 在结直肠癌中，转移大多发生在肝脏，在30%-50%有肝脏受累的患者中，这是唯一的转移部位。对于那些仅有肝转移的患者，切除这些病灶可提供长期生存甚至治愈的机会（例如，5年生存率为25%-71%）。4,6-13 在此，我们重点关注针对最初不可切除肝转移患者的化疗最新进展，旨在使此类病灶可切除，从而有可能提高生存率。4,13,14
